SELLAS Life Sciences (SLS) Stock Surges 255% as Phase 3 Leukemia Trial Hits Key Milestone

TLDR

• SELLAS Life Sciences (SLS) stock is up 255% year-to-date as traders position ahead of Phase 3 REGAL trial data for cancer drug galinpepimut-S in acute myeloid leukemia
• The trial has hit the 80-event threshold required to trigger final analysis
• A new Haematologica study suggests current standard treatments may be less effective than thought, potentially benefiting SELLAS’s drug
• Institutional ownership is rising, with Quantinno Capital Management taking a new $315,000 position in Q1
• Analyst consensus sits at “Hold” with a price target of $10.00, well below the current trading price of $15.46

SELLAS Life Sciences (SLS) stock opened at $15.46 on Monday, near its 52-week high of $15.88, after a year-to-date run of over 255%. The stock has a 52-week low of $1.39, which shows just how much ground it has covered in a short time.

SELLAS Life Sciences Group, Inc., SLS

The catalyst driving recent momentum is the Phase 3 REGAL trial for galinpepimut-S, SELLAS’s cancer drug targeting acute myeloid leukemia. The trial has now reached the 80-event threshold needed to trigger its final data analysis. That milestone is putting the stock on traders’ radars.

… Continue reading the full article at the original source below.